Drug intelligence / Profile preview

anastrozole + letrozole

Development stage: Unknown
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral

Overview

Anastrozole and letrozole are both aromatase inhibitors used to treat hormone receptor-positive breast cancer in postmenopausal women. They work by inhibiting the enzyme aromatase, which reduces estrogen production in the body. Letrozole has been shown to suppress estrogen to a greater degree than anastrozole, though both drugs have similar side effect profiles and efficacy outcomes in clinical trials.

Brand names: FemaraArimidex
Other names: none

Targets

CYP19A1 (Aromatase)

Beyond the preview

Go deeper on anastrozole + letrozole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anastrozole + letrozole.

Explore the full profile